When the Chevrolet Bolt EV first arrived roughly a decade ago, it was celebrated for making longish-range electric driving feel attainable. Our first impressions also found a car with a feisty 200-hp ...

General Motors has released a service update covering a small number of 2026 Chevy Silverado HD and GMC Sierra HD trucks that may have a missing or loose transmission control valve body bolt.

After 4 years absent from the market, the Chevrolet Bolt is back. A small, practical hatchback, the discontinued Bolt was always one of my favorite EVs. And towards the end of its last generation's ...

"We got rid of our HR team." For most executives, that's a sentence likely to provoke intense anxiety. But for Bolt CEO Ryan Breslow, it was unavoidable. Speaking at Fortune's Workforce Innovation ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The 2027 Chevrolet Bolt is positioned as America's most affordable EV, starting under ...

Chevrolet dropped the Bolt, its smallest and least expensive EV, from its lineup just under three years ago. The brand announced production plans for a second-generation car a few months later, and ...

However, the new Bolt isn’t all-new. It’s based on the previous-generation Chevy Bolt EUV, sold during the 2022 and 2023 model years, and rides on the same GM BEV2 platform and vehicle structure, ...

I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...

The 2027 Chevrolet Bolt returns as America’s cheapest EV, offering 255 miles of range, 150 kW fast charging, and advanced tech for under $30K. While the 2027 Bolt’s exterior design is similar to the ...

The Bolt is back, at least for now. Chevrolet’s least expensive electric car disappeared after 2023, but an upgraded version is set to return early next year as a 2027 model. If you’re interested in ...

Bolt Biotherapeutics has halved its workforce for the second time in two years as the oncology biotech delays a readout of its lead immunotherapy. The company had previously been expecting initial ...